Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic response modifiers in acute lymphoblastic leukemia

J G Gribben1, A A Cardoso, J L Schultze

  • 1Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Leukemia
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alveolar macrophages upon pulmonary β-glucan-induced inflammatory adaptation.

Nature immunology·2024
Same author

An abrupt increase in foliage ABA levels on incipient leaf death occurs across vascular plants.

Plant biology (Stuttgart, Germany)·2022
Same author

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence.

Nature communications·2021
Same author

A cross-species approach to identify transcriptional regulators exemplified for Dnajc22 and Hnf4a.

Scientific reports·2017
Same author

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.

Leukemia·2017

Cancer cells often fail to activate T-cells due to insufficient costimulatory signals, leading to anergy. Overcoming this requires reversing T-cell anergy and effective tumor antigen presentation for successful immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • T-cell mediated immune responses against tumors are often clinically insignificant.
  • Cancer cells may be inefficient antigen-presenting cells, failing to provide necessary co-stimulatory signals for T-cell activation.
  • T-cell activation requires both antigen-specific signals and co-stimulatory signals, with the absence of the latter leading to anergy (T-cell nonresponsiveness).

Purpose of the Study:

  • To investigate the mechanisms underlying T-cell anergy in the context of cancer.
  • To identify strategies for overcoming T-cell anergy and enhancing anti-tumor immune responses.
  • To explore the requirements for effective T-cell activation against B-cell malignancies.

Main Methods:

  • The study discusses the dual-signal model of T-cell activation, involving antigen presentation and co-stimulation (e.g., B7/CD28 pathway).

Related Experiment Videos

  • It reviews the concept of anergy and its induction by antigen presentation without co-stimulation.
  • The abstract outlines potential strategies for reversing anergy, including interleukin-2 exposure and CD2 pathway signaling.

    • Main Results:

    • Tumor cells must either express co-stimulatory molecules (like B7) or be presented by efficient antigen-presenting cells to induce T-cell proliferation.
    • Simple expression of B7 on tumor cells alone is insufficient to reverse established T-cell anergy.
    • Reversal of anergy is a complex, multi-step process requiring prolonged interleukin-2 exposure, CD2 signaling, and subsequent antigen presentation with B7 co-stimulation.

    Conclusions:

    • Effective immunotherapy for B-cell malignancies necessitates strategies to reverse existing T-cell anergy in patients.
    • Successful anti-tumor immunity requires both effective tumor antigen presentation and overcoming T-cell unresponsiveness.
    • Future therapeutic approaches should address both the tumor's ability to present antigens and the host's T-cell activation status.